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Abstract
Autologously prepared bone marrow aspirate concentrates, have the potential 
to play an adjunctive role in various patient pathologies that have not been able 
to heal with conventional treatment modalities. The use of bone marrow aspirate 
(BMA) and concentrates in regenerative medicine treatment plans and clinical 
applications is based on the fact that bone marrow cells, including progenitor 
and nucleated cells, platelets, and other cytokines, support in tissue healing 
and tissue regenerative processes. The use of concentrated BMA cells focuses 
primarily on mesenchymal stem cells (MSCs), with the ability to self-renew and 
differentiate into multiple cell types. Concentrated bone marrow cells can be 
retrieved from harvested BMA and ensuing minimal manipulative cell process-
ing techniques, executed at point of care (POC). The application of bone marrow 
biological therapies may offer solutions in musculoskeletal pathologies, spinal 
disorders, chronic wound care, and critical limb ischemia (CLI), to effectively 
change the local microenvironment to support in tissue healing and facilitate tis-
sue regeneration. This chapter will address the cellular content of bone marrow 
tissue, harvesting and preparation techniques, and discuss the biological char-
acteristics of individual marrow cells, their inter-connectivity, and deliberate on 
the effects of BMA concentration.
Keywords: regenerative medicine, bone marrow aspiration, niche 
microenvironment, bone marrow concentrate, centrifugation, hematopoietic stem 
cells, mesenchymal stem cells, differentiation, immunomodulation
1. Introduction
The objectives of regenerative medicine applications are to support the body to 
form new functional tissues to replace degenerative or defective ones and to provide 
therapeutic treatment for conditions where conventional therapies are inadequate. 
The human body has an endogenous system of regeneration through stem cells, 
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as they are found almost in every type of tissue. Regenerative medicine treatment 
options using autologous stem cells can be safely executed by well-trained physi-
cians at point of care (POC). This review is not meant to be exhaustive, but our 
aims are to shed light on the bone marrow progenitor and stem cell mechanisms and 
highlight present and future applications of autologous bone marrow-derived stem 
cells in this exciting new regenerative medicine discipline.
In this chapter a definition is provided on embryotic and non-embryotic stem 
cells, followed by an intensive review of non-embryotic autologous adult stem cells. 
The use of allogeneic MSCs, the fabrication of engineered constructs by seeding of 
natural or synthetic scaffolds with cells, released from autologous tissues will not be 
presented in this chapter, as only relatively few of these cell-based approaches have 
entered the clinical arena. In particular, we deliberate on the biology and clinical 
application of mesenchymal stem cells originating from freshly harvested bone 
marrow. We portray on the techniques of a marrow harvesting procedure using 
ultrasound and fluoroscopic techniques. Explicit scientific information is provided 
on the bone marrow aspirate cellular content, their specific biological functions and 
intercellular interactions, as these, among others, contribute to tissue regeneration 
following clinical regenerative medicine applications. Furthermore, we underline 
the differences between bone marrow aspirate and, centrifugated, bone marrow 
aspirate concentrate injectates, both prepared at point of care from freshly aspirated 
marrow.
Finally, a condensed literature review addressing a variety of clinical ortho-
biological indications, spinal disorders, chronic wounds, and critical limb ischemia 
is provided. Regenerative medicine technologies, using marrow-derived mesen-
chymal stem cell-based therapies, as part of the regenerative medicine treatment 
armamentarium, offer solutions to a number of undeniable clinical conditions that 
have not been able to adequately result in a solution through the use of medicines or 
surgeries.
2. What are stem cells?
Becker, McCulloch, and Till first conducted experiments that lead to the dis-
covery of stem cells in 1963. After injecting bone marrow cells into irradiated mice, 
nodules developed in proportion to the number of bone marrow cells injected, and 
they concluded that each nodule arose from a single marrow cell. At a later stage, 
they produced evidence that these cells were capable of endless self-renewal, which 
is as we know now, a fundamental feature of stem cells [1]. A stem cell is a type of 
cell that is non-specific/specialized in its function; in contrast, for instance, a heart 
or brain cell is functionally specific.
Generally, we recognize two types of stem cells, embryonic and non-embryonic, 
with two defining properties. Firstly, they have the capacity of self-renewal, there-
fore giving rise to more stem cells. Secondly, they are capable of differentiating into 
different lineages under appropriate conditions.
Embryonic stem cells (ESCs) are obtained from 5- to 12-day-old embryos, 
and they are pluripotent and have a high plasticity as they can differentiate into 
ectoderm, mesoderm, and endoderm layers, whereas non-embryonic stem cells 
(non-ESCs) are multipotent, and it appears that they are able to form multiple cell 
lineages which form an entire tissue, usually specific to one germ layer, e.g., adult 
stem cells [2].
The capability for stem cell potency, in combination with the relative ease 
to prepare bone marrow stem cell injectates, is an invaluable property for 
3The Rationale of Autologously Prepared Bone Marrow Aspirate Concentrate for use…
DOI: http://dx.doi.org/10.5772/intechopen.91310
regenerative medicine cell-based therapies in general and more specifically to 
treat, e.g. musculoskeletal disorders (MSK-D), chronic wounds, and critical limb 
ischemia.
2.1 Non-embryotic autologous adult stem cells
Non-ESCs are undifferentiated, and their proliferation potential compared to 
embryogenic stem cells is limited, as they have lost their pluripotent capability, 
placing them lower in the stem cell hierarchy. Nonetheless, it has been suggested 
that non-ESCs maintain their multipotent differentiation potential. Since they are 
categorized as allogenic products, they are commercially prepared from several 
allogenic sources, like amniotic fluid, umbilical cord, and Wharton’s jelly [3]. In this 
chapter we will only deliberate on non-embryotic, autologous adult bone mar-
row aspirate (BMA)-derived progenitor/stem cells and other bone marrow (BM) 
stromal cells, prepared at POC with dedicated and approved centrifuges for BM 
concentration.
2.2 Bone marrow-derived stromal cells
Friedenstein and colleagues reported first on the isolation of bone marrow-
derived stem cells from BM stroma and incubated it in plastic culture dishes and 
identified mesenchymal stem cells as colony-forming unit fibroblasts (CFU-Fs) 
[4]. The BM stroma is made up of a network of fibroblast-like cells and includes 
a subpopulation of multipotent cells which are able to generate the mesenchyme, 
known as the mass of tissue, that develops mainly from the mesoderm of the 
embryo subpopulation. The cells are referred to as mesenchymal stem cells 
(MSCs) [5]. The Friedenstein culture method revealed that MSCs are capable of 
differentiating into several connective tissue cell types [6], described first by 
Pittenger and associates [7].
3. Bone marrow anatomical structure
The bone is an organ composed of cortical and trabecular bone, cartilage, and 
hematopoietic and connective tissues. The bone tissue has an essential role in 
the structure and protection of the human body. Spongy, or trabecular bone, is 
composed of a lattice of fine bone plates filled with hematopoietic marrow, fat-
containing marrow, and arterial-venous sinusoidal blood vessels. Furthermore, it 
consists of bone cells at different developmental stages (including pre-osteoblasts, 
osteoblasts, and osteocytes), collagen fibrils, and calcium and phosphate deposits 
[8]. Arterial vessels enter the marrow through foramina nutricia and then divide 
into several arterioles. Small arterioles and capillaries from these vessels span 
throughout the bone marrow and supply sinusoids, which are interconnected by 
inter-sinusoidal capillaries [9]. The BM tissue is soft, similar to the peripheral 
blood, flexible connective tissue comprising the center and the epiphysis of bones, 
referred to as the BM cavity. In this place a variety of new blood cells are produced 
and ultimately released to the peripheral circulation.
3.1 Red and yellow bone marrow
We recognize two categories of bone marrow tissue: the red and yellow marrow. 
Depending on age, teh red marrow is replaced by the yellow marrow. In adults, the 
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red bone marrow is a rich source of bone marrow-derived cells and present in most 
skeletal system bones of the iliac crest, tibia, spine vertebrae, humerus, calcaneus, 
ribs, and near point of attachment of long bones of legs and arms. In this well-
shielded environment, an estimate of 500 billion cells per day can be produced, in 
particular erythrocytes, granulocytes, and platelets [10]. Regenerative medicine 
applications have a focus on the use of the red bone marrow as it contains myeloid 
and lymphoid stem cells and MSCs. In contrast the yellow marrow consists primar-
ily of fat cells with poor vascularity and is deprived of the multipotential MSCs [11].
3.2 Bone marrow-specific regions
The BM cavity in the trabecular bone is subdivided into four regions: endosteal, 
sub-endosteal, central, and perisinusoidal regions [12]. In Figure 1, the four regions, 
according to the model of Lambertsen and Weis, have been adopted and modified 
[13]. In general, the bone marrow consists of a hematopoietic component (paren-
chyma) and a vascular component (stroma). The parenchyma includes hematopoi-
etic progenitor and hematopoietic stem cells (HSCs), which are localized close to 
the endosteum and around the blood vessels. BM stroma cells, including endothelial 
cells, are recognized as multipotential non-hematopoietic progenitor cells, capable 
of differentiating into various tissues of mesenchymal origin, including osteoblasts, 
chondrocytes, tenocytes, endothelial cells, myocytes, fibroblasts, nerves, and 
adipocytes, as verified in in vitro and partially in in vivo research [14, 15]. The 
bone marrow’s microvasculature includes single layers of endothelium arising in 
sinusoids, where they also contribute in rolling extravasations of leukocytic cells into 
and out of the BM tissue structures. The function of the vasculature and BM-derived 
endothelial cells is that they provide a barrier between the BM compartment as a 
functional and spatial entity from the extra-lymphoid BM section and the peripheral 
circulation, as described by Kopp et al. [9]. The endothelial cells likewise contribute 
Figure 1. 
Bone marrow subdivisions. On the left side, the Aspire introducer (Aspire Bone Marrow Harvesting System™, 
EmCyte Corporation, Fort Myers, FL, USA) has passed the cortical bone entering the marrow cavity. The 
harvesting cannula is inserted through the introducer in the marrow cavity. On the right side, a representation 
of the subdivisions in the bone marrow cavity subdivisions is indicated, showing the endosteal, sub-endosteal, 
central, and perisinusoidal regions. The endosteal and sub-endosteal regions compose the endosteal niche, 
harboring the proliferative and quiescent HSC-MSC niches. The marrow tissue is extracted via the side holes of 
the harvesting cannula (adapted and modified from Lambertsen and Weis [13]).
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to tissue regeneration, as endothelial precursor cells are essential in improving 
vascularization of damaged and degenerative tissue cells by the secretion of pro-
angiopoietic factors of invading cells [16].
3.3 Bone marrow niches
A niche is defined by anatomy and function. Stem cell niches are defined as 
specific cellular and molecular microenvironments regulating stem cell and progeni-
tor functions. A niche consists of signaling molecules, intercellular contact, and the 
interaction between stem cells and their neighboring extracellular matrix (ECM). 
This three-dimensional microenvironment is thought to control genes and proper-
ties that define “stemness,” including the control and balance between quiescence, 
self-renewal, proliferation, and differentiation of diverse cell types. Additionally, the 
microenvironment provides stem cell autonomous signaling mechanisms [17, 18], 
and it engages in specific cascades to a stress response [19]. Acquired and prepared 
BM stem cells from one of the niches and subsequently injected into a totally dif-
ferent microenvironment can potentially differentiate into cell types of this new 
environment [20]. Zhao et al. used a rat stroke model in which BM-MSCs were 
transplanted into neural tissues. They demonstrated that MSCs originating from 
the BM-MSC niche differentiated into neuronal cells after transplantation into the 
neural microenvironment [21]. Their observation revealed the plasticity potential 
of BM-MSCs, as well as the possible influence of the recipient niche, as BM-MSCs 
were capable of dedifferentiation into cells from other cell lineages. Their finding has 
potentially significant clinical implications for regenerative medicine applications 
overall. Since autologously prepared MSCs originate from their specific and original 
BM niche but are used in other cellular tissue types to treat various pathologies, they 
can be successfully engaged in tissue repair and regeneration through regenerative 
medicine application techniques. This is a distinctly different approach in the physi-
ological release of newly formed BM cells, because they are retained in the BM cavity 
until they mature and thereafter released in the vascular peripheral circulation [15].
3.3.1 Hematopoietic and mesenchymal niche
HSC niches are present in various (prenatal) tissues, like the aorta-gonad-
mesonephros region and the yolk sac, followed by the placenta, fetal liver, spleen, 
and bone marrow. Postnatally, the bone marrow is the primary site of HSC pres-
ence [22]. The model of the HSC niche was first described by Schofield in 1978 
[23], later confirmed by others, to describe the physiologically limited microen-
vironment in which HSCs, MSCs, and their progenitors reside in the bone cavity 
where they are enfolded by BM stromal cells [24], covered by the bony structure 
of the BM cavity. The stem cell niches in bone have been extensively described by 
Yin and Li, providing insights into the actions of osteoblastic and vascular niches, 
revealing central roles for numerous signaling and adhesion molecules [25]. A 
significant portion of these hematopoietic cells is found next to the endosteal 
bone surface, designating a clear role for osteoblasts in the regulation of HSCs and 
thus hematopoiesis [26]. Based on flow cytometry research by Kiel et al., HSCs 
are more likely than other hematopoietic cells to be immediately adjacent to a 
sinusoid, in the trabecular region of the BM [27]. This location suggests that HSCs 
and their niche may be directly, or indirectly, regulated by factors present near 
the bone planes. The HSC niche is comprised of many different niche constituents 
including osteoclasts, endothelial cells, fibroblasts, adipocytes, and the HSC 
progenitor cells [28].
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3.3.2 Perivascular niche
The BM is highly vascularized, with large central arteries branching into 
progressively smaller microvessels like arterioles and transitioning into venous 
sinusoids near the bone (endosteal) surface. Therefore, it has been suggested that 
HSCs are maintained in a perivascular niche by endothelial or perivascular cells, 
as they are frequently located adjacent to the blood vessels [29]. These occur-
rences resulted in the expression of various perivascular mesenchymal cell makers 
CD146, stromal cell-derived factor-1 (SDF-1) also referred to as CXCL12, and 
Nestin-GFP, defining the heterogenous BM stroma cell composition [9], including 
the MSCs that surround the blood vessels [30]. The more perivascular nature of 
MSC niches was validated by Shi and Gronthos, demonstrating the expression 
of α-smooth muscle actin (αSMA) at perivascular sites, with the immunohisto-
chemical localization of specific CD marker cells [31]. Mores studies confirmed 
the presence of MSCs in BM, expressing a Nestin-GFP transgene, localized and 
attached around the BM blood vessels and part of the perivascular HSC niche [32]. 
Kunisaki et al. indicated that most HSCs do not only have a perivascular presence, 
but they are preferentially located in the BM endosteal regions. The endosteal 
regions contain a complex network of stromal cells as well that have been impli-
cated in HSC maintenance, including arteriolar and venous endothelial cells, 
pericytes, and chemokine (C-X-C) ligand 12 (CXCL12) reticular cells. Their study 
also suggested that quiescent HSCs localize preferentially to small arterioles near 
the endosteum, suggesting that distinct niches may exist for both quiescent and 
proliferating HSCs [33]. From all these findings, it can be concluded that pericytes 
are in fact MSCs, because they can differentiate in osteoblasts, chondrocytes, and 
adipocytes [34].
3.3.3 Megakaryocyte niche
Megakaryocytes (MK) are the precursor cells of blood platelets. BM hema-
topoietic cells are responsible for platelet production. MK may regulate HSCs 
indirectly as they are closely associated with BM sinusoidal endothelium, extend-
ing cytoplasmic protrusions into the sinusoids to produce platelets. A direct 
regulation of HSC by MK through signaling of transforming growth factor beta 
1 was established, with activation of quiescent HSCs and increased proliferation 
rate. In the event of a sudden response to systemic stress signaling, fibroblast 
growth factor-1 as part of the MK growth factor pool will start signaling HSCs and 
will overshadow the TGF-b1 signaling in order to stimulate high volumes of HSC 
expansion [35].
3.4 Extracellular matrix
The role and function of the extracellular matrix (ECM) can be defined as key 
structural-functional components of cell niches, including soluble factors, cell-cell 
contacts, and cell-matrix adhesions present in these microenvironments. ECM com-
ponents include fibrillar proteins, with, among others, collagen fibers, fibronectin, 
and other filamentous network components. The ECM’s mechanical stability is 
provided by collagen [36]. Other significant ECM components supporting the BM 
niches are glycosaminoglycans and mainly hyaluronic acid via its receptor CD44. 
The surface marker is also expressed by MSCs and HSCs [37]. Intracellular signal-
ing in the ECM occurs through cytokine and growth factor membrane receptors, 
similar to the MSC niche. These cytokines and receptor activities contribute to cross 
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talk between ECM components and MSC niches, provoking cell differentiation. 
For instance, Djouad et al. demonstrated that the induction of MSC differentia-
tion towards chondrocytes in articular cartilage was induced and/or influenced by 
molecules from both the MSC niche and the ECM components of this microen-
vironment, leading to chondrogenic differentiation of MSCs [38]. Other studies 
suggested that ECM deposited by microvascular endothelial cells enhances MSC 
endotheliogenesis [39]. In general, no specific ECM components are identified that 
maintain MSCs in their immature state, as a niche matrix would do. However, it 
has become clear that the ECM can regulate MSC differentiation on a solitary basis, 
indicating potential applications for regenerative medicine applications and tissue 
engineering.
4. Bone marrow aspiration procedures
Exploiting BM preparations at POC seeks to overcome the limitations of 
ex vivo MSC culturing. Clinicians utilizing regenerative medicine applications 
have a growing interest in using the concentrated bone marrow products, since 
it is well acknowledged that BM is a plentiful source of MSCs, progenitors, and 
other cells residing in the trabecular part of flat and long bones, acquired via 
appropriately performed BMA procedures [40, 41]. The regenerative medicine 
market is rapidly growing, with many procedures performed in musculoskeletal, 
orthopedic, and spinal disorders, wound care management including critical 
limb ischemia, and tissue engineering [42–45]. Several groups have mentioned 
some considerations when performing BM harvesting procedures, addressing 
a variety of factors that have an impact on patient comfort and the quality of 
the harvested BM. Emphasis was given to procedural safety issues when using 
harvesting needle systems, level of experience of the operator, the choice for 
concentration technology and centrifugation devices, and pain management 
[46]. Autologous regenerative medicine BM-MSC applications may range from 
a harvesting a low volume of BM and direct, unprocessed, tissue injection to the 
use of centrifugation protocols to concentrate and filter the BMA prior to inject-
ing it in patients [47].
4.1 Bone marrow harvesting needle systems
Various bone marrow needle harvesting systems are available on the market, 
each with their own proprietary design characteristics and thus marrow aspira-
tion dynamics when transferring marrow cavity cells through a needle system 
into collection syringes. In Figure 2, three different needle systems are shown. 
Potentially, different needle design features might affect the quality and viability of 
the harvested BM tissue, as well as the cellular yields. Therefore, BM needle system 
features and harvesting dynamics are important considerations when considering 
BMA procedures. Physicians have been using a variety of harvesting needles during 
the last decades, including the traditional Jamshidi™ harvesting needle (Ranfac 
Corporation, Avon, MA, USA). Based on design differences, not every BMA is born 
equal, and cellular yields, composition, and viability might vary among harvest-
ing devices. For interpretation purposes, some of the cellular difference between 
two newly developed BMA needle harvesting systems, the Aspire Bone Marrow 
Harvesting System™ and the Marrow Cellution Bone Marrow Aspiration Device™ 
(EmCyte Corporation, Fort Myers, FL, USA, and Ranfac Corporation, Avon, MA, 
USA, respectively) is shown. A significant difference between the two harvesting 
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systems is that the Marrow Cellution device is developed and used by physicians 
for BMA aspiration with direct injection only, without filtration or processing prior 
to patient injection [47]. Therefore, these specimens mimic the marrow cavity 
cellular content and their specific cell concentrations. This includes a red blood 
cell (RBC) content and hematocrit which is similar to the peripheral blood values. 
Conditional negative forces occur with the syringe pull during marrow aspira-
tion; this particular BMA injectate can have high plasma-free hemoglobin (PFH) 
concentrations, which cannot be removed from the injectate. The Aspire™ harvest-
ing system is designed to penetrate the trabecular bone, maintaining a quiescent 
tissue environment during deployment and collection, contributing to a reduction 
in tissue activation, plasma-free hemoglobin content, and clotting. The Aspire™ 
harvesting system is intended to provide a BMA for centrifugation processing, 
leading in this occasion to the creation of PurePRP SupraPhysiologic BMC® 
(EmCyte Corporation, Fort Myers, FL, USA). In Table 1, comparative laboratory 
data between the abovementioned needle systems in a bilateral patient harvesting 
model are disclosed.
Figure 2. 
Bone marrow aspiration devices. (A) Jamshidi™ device (Ranfac Corporation, Avon, MA, USA), with a 
sharp and open distal tip, allows for more peripheral blood aspiration. (B) Aspire Bone Marrow Harvesting 
System™ (EmCyte Corporation, Fort Myers, FL, USA) consists of a separate trocar introducer and aspiration 
needle with a completely closed and blunt tip. The side holes of the aspiration needle are designed to minimize 
cellular trauma and hemolysis during aspiration. (C) Marrow Cellution Bone Marrow Aspiration Device™ 
(Ranfac Corporation, Avon, MA, USA) is used as an aspiration device only, to aspirate 10 ml of bone marrow, 
followed by unfiltered injection.
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4.2 Large vs. small BMA collection syringes
In theory, a larger-volume BMA collection syringe should produce a stronger 
negative pressure and therefore harvest more MSCs. However, Hernigou et al. found 
that the aspiration of only 10–20% of the full syringe volume resulted in a higher 
MSC concentration in both 10 and 50 ml syringes, indicating that high-quality 
harvesting of MSCs requires a significant negative pressure in the marrow cavity 
to liberate MSCs. They also concluded that the collection of MSCs decreased as the 
syringe was filled, at a lower negative pressure [40]. Therefore, smaller syringes and 
thus smaller aspiration volumes result in higher MSC concentrations than with larger 
aspiration volumes [48]. This translates to the physical equation, “Negative Pressure 
= Pull Force/Plunger Surface Area,” resulting in the fact that with the same pull force 
and a smaller diameter syringe plunger, a higher negative pressure is created [49]. 
Lately, the authors use 10 ml syringes, employing a fast and intermittent pull tech-
nique to collect small volumes from different intra-trabecular sites (Figure 3). This 
is in accordance with a trend towards small-volume HPD aspiration techniques [50]. 
Another advantage for using 10 ml syringes is that anticoagulation protocols can be 
better managed. Smaller syringes fill considerably quicker than larger syringes, and 
smaller syringes can be adequately agitated with the anticoagulant to avoid clotting.
4.3 Image-guided aspiration
In order to perform BM-MSC procedures, a certain volume and quality of mar-
row tissue are required in order to prepare a bone marrow concentrate (BMC). The 
aspiration volume is contingent on the processing volume of the BMC concentration 
system that is being used. It is imperative to locate precisely the donor site, as MSCs 
are located in the marrow cavity subcortical area and around the blood vessels [19]. 
The precise delivery of local anesthetics and safe trocar placement are accomplished 
by using image guidance during aspiration procedure. In the following section, 
we focus on the posterior super iliac spine (PSIS) sites, as it is the most frequently 
reported anatomical site for BMA.
Laboratory parameters BMA-MC
10 ml
BMA-A
10 ml
BMC
11 ml
TNC × 106/mL 25.8 31.8 73.7
Platelets × 106/mL 117 117 576
CD34+ (HSCs) × 105/mL 1.42 1.12 2.51
CFU-F (MSCs) × 103/mL 446 1.13 837
Hematocrit % 36.2 36.2 9.8
RBCs × 109/mL 4.02 4.08 1.44
PFH mg/dl 913 721 299
Hemolysis % 4.6 3.2 1.6
Cell viability % 94.4 94.4 96.8
BMA-MC, bone marrow aspirate Marrow Cellution System; BMA-A, bone marrow aspirate Aspire System; BMC, 
bone marrow concentrate; TNC, total nucleated cells; CD34+, hematopoietic stem cell marker/expression in bone 
marrow; CFU-F, colony-forming unit fibroblast: assay for bone marrow mesenchymal stem cell analysis, MSCs, 
mesenchymal stem cells. (BMA-MC, Marrow Cellution Device™—Ranfac Corporation, Avon, MA, USA; BMA-A, 
Aspire Bone Marrow Harvesting System™—EmCyte Corporation, Fort Myers, FL, USA).
Table 1. 
Comparative quantification between two different bone marrow aspiration systems and bone marrow 
concentrate, in a bilateral patient model.
Regenerative Medicine
10
4.3.1 Ultrasound imaging
When the PSIS is targeted, patients are positioned in the prone position, while 
avoiding lumbar lordosis. Sonographic assessment using a portable ultrasound 
system with a 5–2 MHz low-frequency curvilinear transducer is positioned in a 
transverse plane over the hyperechoic bilateral sacral cornua, with the patient lying 
prone and the monitor screen in the line of sight of the operator. The probe is then 
translated contralaterally from the physician, keeping the hyperechoic sacrum visu-
alized. Next, the probe is translated proximally, with the hyperechoic ilium coming 
into view, while maintaining the hyperechoic sacrum, until the most superficial 
depth of the ilium is reached, known as the PSIS, contralateral to the examiner 
[51]. After identification of the PSIS, the most superficial depth is confirmed in 
both transverse and longitudinal orientation (Figure 4). With the probe in the 
transverse plane at the PSIS, the slope of the iliac wing is noted for correct angula-
tion of the BM trocar, and the most superficial depth of the PSIS is brought under 
the most medial aspect of the ultrasound probe. Using a sterile marker, a mark and 
Figure 3. 
Bone marrow aspiration. After the aspiration needle has been advanced in the marrow cavity, the marrow is 
extracted using a firm, but a gentle, aspiration pressure is applied to the 10 ml syringe. The aspiration needle is 
easily rotated to collect marrow from a fresh area.
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directional line is made in both parallel and perpendicular orientations to form an 
intersection at the most superficial depth of the PSIS. This mark is maintained on 
the patient during skin preparation prior to the introduction off the BM trocar, and 
a superficial wheal of local anesthetic is placed at the point of planned trocar skin 
entry. Following the local antiseptic measures, sterile ultrasound gel is applied at 
the marked area, and a sterile probe cover is applied to the 5–2 MHz curvilinear 
array transducer. Typically, a mixture of local anesthetics is injected around the 
PSIS cortex and periosteal sleeve, under continued sonographic guidance, making 
sure to “walk off” the PSIS in four directions (superiorly, medially, laterally, and 
inferiorly), confirmed by sonographic guidance. The trocar is then introduced, 
using either a manual force that is perpendicular and slightly lateral to the patient, 
at 9–12 counterclockwise-clockwise rotations, or a mallet. The next steps of the 
procedure are subject to the implementation of the instructions for use provided by 
the manufacturer of the aspiration harvesting system.
4.3.2 Fluoroscopic imaging
After proper patient positioning, the fluoroscopic equipment is installed to 
optimize the positioning for fluoroscopic imaging, using ipsilateral or contralateral 
oblique beam angulations for viewing the targeted PSIS site. The perpendicular 
fluoroscopic approach requires a beam angle around 15° ipsilateral to the PSIS 
entering laterally with angulation towards the sacroiliac joint. This angle will view 
the lateral ilium outer wall, and a needle is directed anteromedially. Fluoroscopic 
images support in positioning the tip of the trocar above the target area for enter-
ing the PSIS. The parallel fluoroscopic approach results in viewing down the PSIS 
table, at a 25° contralateral oblique beam position. This results in a classic view of 
the “teardrop” (Figure 5). Imaging can confirm the entry point into the PSIS table 
and visualize the angle through the cortex, allowing for safe trocar advancement 
in the BM cavity, at the tick part of the ilium bone [52]. Using proper fluoroscopic 
Figure 4. 
Ultrasound imaging of the PSIS. With the probe in the transverse plane, the PSIS is confirmed, and the slope 
(D) of the iliac wing is noted for correct angulation of the BM trocar (B), and the most superficial depth 
(C) of the PSIS is brought under the most medial aspect of the ultrasound probe. Note: (A) indicates the skin 
surface, and (E) marks the depth of the PSIS below the skin, in this patient approximately 1.6 cm (courtesy of 
J. Rothenberg).
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techniques, the parallel approach technique allows for a safe deeper marrow 
penetration. However, at all times, regardless of the approach, avoid increased 
manipulation and tissue trauma using the sharp trocar, as this will increase the risk 
for neurovascular injury, bleeding, tearing of lateral gluteal muscle origins, and 
post-procedural pain.
4.4 Bone marrow aspiration anatomical sites
As MSCs represent a small population of BM cells [7], it is of critical impor-
tance to choose a BMA site that will yield the most MSCs. BM is relatively easy to 
harvest, largely available, and dispensable. Obviously, it is important that the BMA 
procedure is performed impeccably to obtain an optimal quality of viable BM tissue 
[5, 53]. In humans, the most common anatomical location to obtain BM is the iliac 
crest, but other BMA sites have been utilized (Table 2). Recently, McDaniel and 
co-workers, using a porcine model, reported that all studied anatomical bone mar-
row harvesting locations contained MSCs but the iliac crest was the most abundant 
Anterior superior iliac spine (ASIS)
Posterior superior iliac spine (PSIS)
Proximal tibia
Distal tibia
Distal femur
Proximal humerus
Vertebral body
Calcaneus
Sternum
Table 2. 
Bone marrow aspiration sites in humans.
Figure 5. 
Fluoroscopy imaging of the PSIS. General prone position of the patient on a fluoroscopic table for 
BMA. The parallel fluoroscopic approach results in viewing down the PSIS table, at a 25° contralateral 
oblique beam position. This results in a classic view of the “teardrop,” referring to the outline of the medial 
and lateral borders, as shown in the monitor. The tip of a needle (black circle), in the numbed skin, is 
marking the entry site of the bone marrow trocar to be placed in the marrow cavity, while the physician is 
on the ipsilateral side of the fluoroscope, viewing the correct position on the monitor (red circle) (courtesy of 
G. Flanagan II).
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source of MSCs [10]. These findings were confirmed in a clinical study, where MSCs 
were found in BM acquired from the metaphysis of the distal femur, the proximal 
tibia, and iliac crest. A similar MSC immunophenotype and differentiation poten-
tial (into the bone, fat, and cartilage) were seen in BMA from all sites. However, in 
their study the concentration of MSCs in the iliac crest was significantly higher than 
in samples from the distal femur and proximal tibia. More specifically, the literature 
indicates high yields of BM-MSCs acquired from the posterior superior iliac spine 
(PSIS) [50, 54]. Noteworthy, the group of Narbona-Carceles commented on the 
relative easiness and safety of lower extremity aspiration techniques [55].
5. Major type of cells in bone marrow
The literature pronounces BMAs as a heterogenous mix of cells, referring in 
most instances to MSCs, HSCs, and mononuclear cells. Platelets, megakaryocytes, 
and RBCs are seldomly mentioned, let be subject to BM research [24].
5.1 Hematopoietic stem cells
The major function of the bone marrow is to generate blood cells. In particular 
in adults, marrow-derived HSCs are the principle cells of origin of all mature hema-
topoietic cell phenotypes. HSCs are adult stem cells with extensive self-renewal 
capabilities and are able to differentiate into specialized blood cells with key roles 
in some biological activities: control homeostasis balance, immune functions, and 
response to microorganisms and inflammation. Most HSCs are in a quiescent state 
within the BM niches. They respond to the signals after the balance of blood cells, 
or HSC pool, is disturbed from either intrinsic or extrinsic stimuli and signaling 
processes [56].
5.1.1 Hematopoiesis
Hematopoiesis—the process by which mature blood cells are formed—has been 
studied intensely for over a century. The vast majority of hematopoiesis occurs in 
the bone marrow where it must balance enormous production needs. More than 500 
billion blood cells are produced every day, with precise regulation of the number 
of each blood cell type released in the circulation [57]. Hematopoiesis is considered 
as a pyramidal/hierarchical process with cells of greatest maturation potential 
or primitiveness sitting at the top of the hierarchy and cells that have undergone 
terminal differentiation at the bottom. Terminally differentiated blood cells are 
classified into one of the two major lineages: those derived from myeloid lineages 
and from lymphoid progenitors. Myeloid cells include erythrocytes, platelets, and 
cells responsible for cellular immunity, such as macrophages and granulocytes 
(Figure 6). Cells derived from lymphoid progenitors are major participants in 
coordinating humeral and cellular immunity. Experimental data suggested that 
HSCs differentiate into hematopoietic progenitor cells that are capable of exponen-
tial proliferation as well as continuing the process of differentiation. Alternatively, 
HSCs are capable of self-replicating activities, which may give rise to one or two 
identical daughter cells. As a result, HSC activity must be tightly regulated to 
meet physiologic demands but also to protect HSCs from oncogenic, physical, and 
chemical damage to occur. The site or physical location that regulates self-renewal, 
proliferation, and differentiation of HSCs has been discussed in the HSC niche 
paragraph.
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5.1.2 HSC and angiogenesis
Emerging evidence suggests that BM-derived endothelial cells and HSCs, includ-
ing their progenitor cells, contribute to tissue vascularization. HSCs deliver specific 
angiogenetic factors, facilitating the incorporation of endothelial progenitor cells 
into newly sprouting vessels. Several clinical studies have shown that BM-derived 
cells contribute to neo-angiogenesis during wound healing [44], critical limb 
ischemia [45], and postmyocardial infarction [58]. This should contribute to the 
clinical discussion of the value of BM-derived HSC and vascular progenitor as they 
are able to contribute to tissue restoration by accelerating tissue vascularization and 
regeneration [15, 59].
5.2 Mesenchymal stem cells
In recent decades, physicians performing regenerative medicine applications 
have been more interested in the potential of BM-MSCs than of HSCs. Imaginable 
reasons for this particular interest in MSCs might be recent published expert 
opinions: the in vivo ability of MSCs to migrate into tissues, their sturdy regenera-
tive and reparative properties, and the MSC-mediated immunomodulatory actions. 
Figure 6. 
Hematopoietic stem cell hierarchy. Self-renewing HSCs give rise to common myeloid progenitors 
and common lymphoid progenitors, producing different types of progenitor cells and ultimately fully 
differentiated cells. The myeloid progenitors produce granulocyte-macrophage progenitors giving rise to 
differentiated leukocytic cells and mast cells. The megakaryocyte/erythrocyte progenitors give rise 
to megakaryocytes, platelets, and erythrocytes. The lymphoid progenitors differentiate ultimately in 
lymphocytic cell variances.
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These typical characteristics and particular mode of actions enable conceivable BM 
cell-based treatment options [60, 61]. In particular, MSCs do not express signifi-
cant histocompatibility complexes and immune-stimulating molecules, leading to 
graft rejection. Likewise, a rapid development in clinical outcome reporting, with 
a better understanding of BM tissue molecular biology, improved bone marrow 
aspiration techniques and, at POC BM concentration and preparation methods, 
has increased the interest and demand for autologous BM stem and progenitor cell 
therapies.
5.2.1 MSC isolation procedure from bone marrow aspirates
An effective BM-MSC injection is reliant on the performance of the marrow 
aspiration procedure, minimizing cellular trauma, while maximizing cellular 
yields and simultaneously avoiding peripheral RBC infiltration [62]. BM aspiration 
procedures, and not diagnostics, are routinely performed to collect bone marrow 
tissue to be processed using dedicated BM-MSC concentration kits for regenera-
tive medicine applications. Kits may include a harvesting needle system and/or 
BM concentration device (Figure 7). These at POC MSC isolation techniques are 
a streamlined method to concentrate marrow cells, including MSCs, HSCs, and 
progenitor cells. These MSC centrifugation procedures demand less time and 
attention than laboratory preparation and culturing methodologies which are 
technically demanding. Double-spin centrifugation protocols create a layered BMC 
buffy coat stratum, based on different centrifugal forces that accomplish density 
cellular separation, as a result of the specific cellular gravity of the individual mar-
row components, as shown in Figure 8. Furthermore, BMA concentration-based 
technologies provide an economic and clinical/patient advantage when compared 
to the culturing technologies.
Figure 7. 
Bone marrow preparation essential components. In bone marrow concentration and preparation kits, the 
foremost components are a bone marrow harvesting needle and a concentration device (courtesy of EmCyte 
Corporation, Fort Myers, FL, USA).
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5.2.2 MSC culturing protocols
Traditionally, BM-MSCs have been separated from other BM cells following 
strict laboratory cell processing protocols. These cell processing techniques are 
lengthy procedures, as they cannot be performed at POC, as a same-day proce-
dure. In many parts of the world, clinicians are allowed to use autologous, fresh, 
and non-cultured BMA and BMC products that are prepared at POC. In the USA, 
regenerative medicine biological procedures demand the use of the so-called 510-K 
FDA-approved devices. The use of MSCs following laboratory expansion techniques 
is facing considerable legislative barriers. Furthermore, the literature has cited 
potential risks associated with laboratory MSC cell processing techniques, like 
tumorigenicity [63], genetic instability [64], and immunogenicity [65]. Others raise 
concern regarding the efficacy and function of cultured MSCs by in vitro culture 
conditions during the cell passages for cell expansion. Karp and Teo reported on the 
loss of specific MSC surface receptors functions, negatively affecting chemotaxis 
[66]. Others have informed on impaired homing abilities and disappearing CXCR4 
receptors following cell culturing, when compared to non-cultured BMA, in which 
high CXCR4 concentrations were measured [67]. Last but not least, laboratory MSC 
cell culturing methods for regenerative medicine practices require the availability 
of a specialized and dedicated facility, using strict regulatory protocols which will 
increase costs [68].
5.2.3 Characterization of bone marrow mesenchymal stem cells
In order to better understand the specifics of MSC cell concentrations, counts, 
and quality, it’s important to understand the differences between laboratory tech-
niques analyzing HSCs and MSCs, as they differ with regard to the specificity 
Figure 8. 
Bone marrow gravity separation following centrifugation. (A) Bone marrow aspirate in concentration device 
before centrifugation. In (B), the bone marrow aspirate is concentrated, with a view on the buffy coat stratum 
(gray layer on top of the RBC layer), referenced by the two black lines. Following a two-step centrifugation 
protocol, the centrifugal forces achieve density marrow cell separation due to the specific gravities of the 
individual marrow components.
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and relevance of the different BM cell types, possibly effecting regenerative 
medicine therapy outcomes.
5.2.3.1 ISCT criteria
The International Society of Cellular Therapy (ISCT) has developed criteria in 
order to outline human MSCs for both laboratory-based scientific investigations 
and for preclinical studies [69]. MSCs are defined as those cells that are able to 
adhere to plastic and express a number of cell surface markers while undergoing 
multilineage differentiation [70].
5.2.3.2 Flow cytometry and CD markers
It has been difficult to determine what type of cells is neighboring both MSCs 
and HSCs and contributes to the regulation of the functional continuation of 
stem cell, as immunostaining methods are complex procedures to perform. Flow 
cytometry is a laboratory technique used to detect and measure characteristics of 
cell/particle populations by measuring their physical and chemical properties. A 
specific protocol for the identification of dissimilar cell surface molecules is called 
cluster of differentiation (CD) where monoclonal antibodies (markers) are used to 
establish positive and negative staining for certain cell types. Specifically for MSC 
and HSC, explicit CD markers are established to validate BM cellular content, as it 
is widely accepted that MSC cultures are a heterogenous source of cells with varying 
self-renewal and differentiation properties [71]. This indicates that there is no single 
unique indicator for identification. Hence, a panel of both positive and negative 
protein markers is used to identify the cell surface markers that are expressed by 
MSC populations, like CD29, VD44, CD51, CD73, CD90, CD105, CD166, and Stro1. 
While they must be negative for hematopoietic stem cell markers like CD14, CD34, 
and CD45 [72], some of these markers are included in the minimum ISCT criteria.
5.2.3.3 Colony-forming unit fibroblast assay
In the initial BM monolayer, several hematopoietic oriented cells (macrophages, 
endothelial cells, and lymphocytes) adhere to plastic [7]. Nevertheless, in culturing 
conditions only fibroblast-like spindle-shaped cells proliferate and form ultimately 
CFU-F colonies. These cells are representative of the more highly proliferative 
cells in MSCs [73]. The CFU-F assay is a different method used to determine the 
MSC presence in a vial of BM tissue. Unlike a complete blood count test, which is a 
quantitative blood cell analysis, the CFU-F assay is a laboratory assay in particular 
for stem and progenitor cell determination (Figure 9) [74]. The CFU-F assay is a 
qualitative indicator of the proliferative and differentiation capability of individual 
MSC cells within a BMA or BMC sample. The cells are seeded and cultured in a 
growth medium where they have to adhere to plastic, at 37°C. After 14 days the 
cultures are evaluated, and CFU-Fs are counted, whereby a minimum of 50 cells per 
CFU need to be defined.
5.3 MSC capacities
MSCs are multipotent stem cells which can be obtained from various adult 
tissues, like the BM stroma, adipose tissue, synovium, periosteum, and trabecular 
bone. Typical features are their ability for self-renewal, defined as sustaining 
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biological pathways and mechanisms to preserve the undifferentiated stem state, 
and the regulation of lineage-specific differentiation [39]. Although the number 
of MSCs represents only a small fraction of non-hematopoietic, multipotent cells 
of the bone marrow (0.001–0.01%), understanding these unique cells has taken 
great strides forward. Generally, MSCs have developed a great attractiveness for 
regenerative medicine autologous therapeutic applications and tissue engineering 
opportunities, because of their multipotentiality and relative ease of isolation from 
numerous tissues, like BM [75]. MSCs can be also identified as specialized popula-
tions of mural cells or pericytes, sharing a niche with HSCs. Under appropriate 
conditions and an optimal microenvironment, MSCs can differentiate into various 
mesodermal lineages like osteoblasts, chondrocytes, endothelial cells, adipose 
tissue, and smooth muscle cells (Figure 10) [76]. These MSC proficiencies have led 
to the use of MSC as a potential strategy for treating various diseases, since they 
encourage biological processes, for example angiogenesis, cell proliferation, and cell 
differentiation [77]. Furthermore, they synthesize cytokines and trophic mediators 
which participate in tissue repair processes, immune modulation, and the regula-
tion of inflammatory processes [78]. Caplan also suggested that the modulation of 
inflammation is instigated by the suppression of inflammatory T-cell proliferation 
and inhibition of monocyte and myeloid cell maturation [79]. Based on the above 
characteristics, it can be assumed that MSCs are capable to institute a regenerative 
microenvironment at the site of release and improve the various cell recruitment, 
cell-signaling, and differentiation of endogenous stem cells, with the potential to 
instigate tissue repair in a variety of disease states.
5.4 MSC immunomodulatory effects
In parallel with their major role as undifferentiated cell reserves, MSCs have 
immunomodulatory functions which are exerted by direct cell-to-cell contact, 
secretion of cytokines, and/or by a combination of both mechanisms. MSCs have 
been shown to exert profound anti-inflammatory and immunomodulatory effects 
on almost all the cells of the innate and adaptive immune systems via a variety of 
mechanisms, notably cytokine and chemokine secretion [80]. The immunosup-
pressive capabilities of MSCs are only exploited when they are exposed to suffi-
ciently high concentrations of pro-inflammatory cytokines, like interferon-gamma 
(IFN-γ), tissue necrosis factor α, (TNF- α), and interleukins α or ß (IL-1α, IL ß). 
Figure 9. 
MSC culturing. A picture of a flask cultured with stained human MSCs. The zoomed-in area is a light 
micrograph showing the morphology of a MSC colony in a patient treated with BMC. After culturing for 
14 days, the MSC count in this example was 1065/mL (picture courtesy of BioSciences Research Associates, 
Cambridge, MA, USA).
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In order for MSCs to become “immunosuppressants,” they need to be triggered by 
these inflammatory cytokines, and the inflammatory environment is then a crucial 
factor for MSCs to exert their immunomodulatory effects. These are wielded by 
blocking apoptosis of native and activated neutrophils, aside from decreasing 
neutrophils from binding to vascular endothelial cells and the mobilization of neu-
trophils to the area of damage [81]. Furthermore, MSCs constrain the complement-
mediated effects of peripheral blood mononuclear cell proliferation [82], and they 
limit mast cell degranulation and the secretion of pro-inflammatory cytokines, 
while at the same time MSCs migrate towards CXCL12 and other chemotactic 
factors [83]. In Figure 11 the MSC cell-dependent trophic support mechanisms are 
shown. Data from Jiang and others suggested that MSCs can block the differentia-
tion of CD34+ cells from BM or blood monocytes into mature dendritic cells by 
direct contact as well as by secreted paracrine factors [84]. Under their influence, 
M1 (pro-inflammatory) macrophages are transformed into M2-type cells with an 
anti-inflammatory phenotype, and the interleukin-10 secreted by them inhibits 
T-cell proliferation. This immunosuppressive effect related to T-cell proliferation 
and decrease in cytokine production by MSCs was, among others, confirmed 
by Sato et al. [85]. However, the mechanisms by which MSCs are mobilized and 
recruited to damaged sites are not known. In addition, how they survive and 
differentiate into distinct cell types is still not clear. Once MSCs have been applied 
to the microenvironment of injured or degenerated tissues, many factors stimulate 
the release of many growth factors by MSCs; a detailed growth and trophic factor 
overview is shown in Table 3. These growth factors stimulate the development of 
fibroblasts, endothelial cells, and tissue progenitor cells [86]. It is credible to state 
that the use of MSCs and their potential in immunomodulation in regenerative 
medicine applications hold great promise [87].
5.5 MSC growth factor activity
In order for MSCs to differentiate into several cell lineages, the action of specific 
growth factors and chemical mediators are needed in these processes [88, 89]. 
Figure 10. 
MSC differentiation potential. MSC differentiation potential into endodermal, ectodermal, and mesodermal 
lineages. The mesodermal lineage differentiation has been recognized as the most attractive differentiation 
lineages for regenerative medicine applications, executed at point of care, as these produce osteoblasts, 
chondrocytes, tenocytes, adipose tissues, and smooth muscle cells.
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Growth factor/cytokine Activity in MSC regenerative repair
Epidermal growth factor Wound healing
Tissue regeneration
Fibroblast growth factor Tissue repair
Intrinsic stem cell survival
Tissue regeneration
Neurogenesis
Hepatocyte growth factor Vasculogenesis
Intrinsic neural cell regeneration
Insulin-like growth factor Wound healing
Neurogenesis
Keratinocyte growth factor Wound healing
Platelet-derived growth factor Tissue repair
Transforming growth factor beta Wound healing
Vascular endothelial growth factor Angiogenesis
Wound healing
Angiopoietin-1 Angiogenesis
Tissue repair
Erythropoietin Angiogenesis
Interleukin-8 Wound healing
Stem cell-derived factor-1 Neuroprotective effect
Wound healing
Table 3. 
Growth and trophic factors contributing to MSC tissue regenerative processes.
Figure 11. 
MSC trophic mechanisms. After bone marrow cell injections, MSCs produce a variety of trophic factors 
impacting healing cascades by reducing cell apoptosis, fibrosis, and inflammation. Furthermore, by acting on 
cell proliferation cascades, they contribute to differentiation and mobilization of cells. MSC paracrine trophic 
factors are potentially important in maintaining endothelial integrity and promoting angiogenesis and the 
secretion of various growth factors and reparative cytokines.
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Once MSCs are mobilized, or after BM tissue injections, they produce a number 
of trophic factors that impact healing responses. At a local tissue level, they act by 
reducing cell apoptosis, fibrosis, inflammation, and activation of cascades that 
lead to cell proliferation and differentiation, mobilization of cells, and an onset of 
angiogenesis via paracrine and autocrine pathways [90]. Crucial agents involved 
in these processes include a variety of growth factors. The MSC trophic effects are 
associated with the secretion of reparative cytokines and growth factors [91], which 
contribute finally to tissue repair of inflamed and degenerated tissues, retaining 
positive MSC paracrine effects [92]. Many of the MSC growth factors are generated 
on the principle of the cell regulating protein nuclear factor-κB activation, after an 
initial exposure to pro-inflammatory stimuli such as IFN-γ, TNF-α, and IL-1β or 
even hypoxia [93]. These factors most likely coexist in prepared MSC-containing 
BM vials and delivered at tissue injury sites. In this situation, MSC growth factors 
and other cell mediators may have the potential to exert their specific activities via 
molecular interplays and subsequently promote optimal MSC-associated thera-
peutic tissue healing, in particular in a highly concentrated environment [94]. The 
endothelial monolayer barrier function of tissue capillary beds is often disturbed 
under degenerative and inflamed conditions, allowing for the blood to release 
proteins and white blood cells, while MSCs produce and release growth factors that 
affect endothelial cell and subsequently promote the development of tissue pro-
genitor cells and fibroblasts and support tissue regeneration and repair [95]. Some 
clinicians combine platelet-rich plasma concentrations [96] with BM products in 
order to have a more biologically active graft, projected to optimize regenerative 
medicine treatment outcomes. However, it is important to comprehend the detailed 
mechanisms underlying the inflammation-modulated production of growth factors 
by MSCs, as this will provide a better perspective for the clinical application of 
MSCs or their paracrine factors in tissue regeneration.
5.6 MSCs and angiogenesis
MSC paracrine trophic factors are potentially important in maintaining endo-
thelial integrity and promoting angiogenesis through their ability to regulate 
endothelial cell proliferation and ECM production [97]. Furthermore, endothelial 
cell permeability is reduced, and MSCs inhibit interactions between leukocytes 
and endothelial cells [98]. Apart from MSC trophic factors, fibroblasts have fun-
damental functions in maintaining tissue integrity and promote tissue healing 
through their secretion of cytokines that support ECM building. These endothelial 
and angiogenetic capabilities have been demonstrated in clinical studies addressing 
chronic wound healing [99] and recovery from postmyocardial infarction [100].
5.7 Homing and migration
An enduring problem in the field of cell-based regenerative medicine therapies 
is the factual delivery of the harvested and prepared cells to the site of injury, a 
process termed “homing” [101]. One of the major characteristics of MSCs after 
administration is that they are able to migrate to sites of inflammation and tissue 
damage, which are typically associated with cytokine outburst [102]. Homing 
mechanism to degenerated and injured tissue sites are influenced by factors like 
age, cell viability, the number of available cells (dosage), and the delivery method. 
Unlike the well-characterized phenomenon of leukocyte homing by de novo, or 
exogenously delivered (BM) MSCs, is still unclear. Evidently, an increase in leu-
kocyte migration, with induced rolling response to inflamed tissue sites, has been 
noted by engineered MSCs [103]. For successful cell-based regenerative therapies, 
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it is critically important for MSCs to control cell adhesion in the ECM of the treated 
tissue. This will occur through the expression of fibronectin and specific integrin 
and selectin protein adhesion molecules, which are binding to collagen and fibrin 
ECM components [102], initiating tissue healing and regeneration through cell 
adhesion, cell growth, migration, and differentiation [104]. The migration abil-
ity of MSCs is further controlled by a wide range of growth factors, acting under 
the receptor tyrosine kinase signaling principle [105], once more illustrating the 
importance and presence of platelets and their growth factors in the collected BM 
vial. Furthermore, the administration of MSCs via various delivery routes (intra-
venous, intraperitoneal, intra-arterial, in situ injections) seems to have an effect on 
MSC homing [66].
6. Bone marrow aspirate aspiration and processing
When applying regenerative medicine MSC applications, physicians have a 
choice to use either a BMA as a regenerative injectate, without any processing steps, 
or they can harvest a particular BMA volume necessary to produce a BMC, with 
dedicated devices and centrifuges. Additionally, the differences between a BMA 
injectate only and a BMA concentrate are discussed.
6.1 BMA-MSC procedural steps
In the freshly aspirated BMA samples, the heterogenous cellular content is 
pervasively distributed in the vial, as long as clotting is prevented.
6.1.1 Anticoagulation protocol
Prior to a BMA procedure, it is recommended that bone marrow harvesting 
devices, concentration devices, and all of the processing accessories that will be in 
contact with BM are subject to a thorough heparin rinsing. Furthermore, several 
instructions for use advice to leave a volume of anticoagulant in the aspiration 
syringes and processing device as well, as BM tissue has the potential for rapid 
clotting. Before a BMC concentration device is loaded for processing, the aspira-
tion syringes volumes are transferred into one consolidating collection syringe and 
subsequently filtered through a 200u heparin rinsed filter to eliminate particles, 
fibrin strands, and fat tissue.
6.1.2 Two-step BMA centrifugation protocol
It is our belief that the preparation of a vial of concentrated MSCs is best created 
by the so-called double-spin protocols, using dedicated and approved disposable 
concentration devices. BMA centrifugal processing techniques, to produce a viable 
BM-MSC injectate, are generally accepted methods when executed at POC, because 
these preparation protocols seek to overcome the limitations of MSC ex vivo cell 
culturing techniques. In this section we touch on a BMC preparation protocol to 
produce PurePRP SupraPhysiologic Bone Marrow Concentrate (PureBMC®SP, 
EmCyte Corporation, Fort Myers, FL, USA). The PureBMC®SP autologous biologic 
is part of an autologous cellular platform technology, facilitating the preparation 
of platelet-rich plasma and adipose tissue concentrates. A two-step centrifugation 
and preparation protocol will concentrate the indispensable BMA cellular content 
to a BMC. Following a first centrifugation spin, the BMA is sequestered in a BM 
plasma fraction (BMPF), containing a buffy coat layer and RBCs. The BMPF is 
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aspirated, immediately followed by a separate collection of 2 ml of RBCs, following 
the instructions for use of the PureBMC® concentration device. Both volumes are 
then transferred for a second centrifugal spin cycle to the concentration compart-
ment of the same device. During the second spin, a specific centrifugation protocol 
is accomplished, leaving the bone marrow cells in a concentrated fashion attached 
at the bottom of the chamber. Excessive BMPF is manually removed, leaving behind 
a specific BMC volume for resuspension. The amount of this volume depends on the 
requirements for clinical applications. Therefore, the BMC injectate volume may 
vary between 3 and 10 ml, with increased cell concentrations according to this final 
volume varying between 4- and 10-fold the native concentrations.
6.2 Cellular differences between BMA and BMC injectates
In a BMA injectate, the concentrations of the cells resemble the concentration of 
the cells that are present in the bone marrow cavity. However, based on aspiration 
techniques, the number of MSC might be increased. A BMC is a small volume of 
fluid containing a high concentration of cells extracted from the bone marrow, such 
as high yields of MSCs (can be measured as CFU-Fs), HSCs, progenitor cells, total 
nucleated cells, and platelets, at a significant concentration above BMA baseline 
values. Furthermore, the heterogenous nature of marrow cells is completed by the 
presence of increased levels of growth factors [106, 107], cytokines like IL-8, and 
interleukin-1RA [94]. Additionally, in a BMC injectate following a two-step cen-
trifugation procedure, the RBC and plasma-free hemoglobin (PFH) concentrations 
are significantly decreased when compared to a BMA injectate.
6.2.1 Red blood cells and hemolysis
Throughout the aspiration procedure, RBCs can be damaged as a result of high 
shear forces [108]. As a consequence, the RBC membrane will start to disintegrate, 
and hemolysis, with the release of PFH, will occur. Damaged RBCs and free 
hemoglobin (Hb) lead to the development and release of toxic Hb forms, like free 
hemin, ferric Hb, and iron [109]. This is of particular concern as PFH and their split 
products, heme and iron, cannot be cleared, by natural scavenger proteins, when 
bone marrow injectates are applied in any microenvironment, as these are outside 
of the blood stream. A graphic representation of the pathophysiological effects and 
reactions of PFH, leading to various hemolytic-related sequelae and potentially 
encumbering clinical outcomes, is presented in Figure 12.
6.2.2 Comparative laboratory data BMA vs. BMC
In Table 1 the effects of concentrating BMA to BMC with regard to some of the 
most important marrow constituents and factors are shown, as discussed in Section 
4.1. The data in the table represent a clinical bilateral BMA model, using two differ-
ent harvesting systems. For both systems, BMA was aspirated in an identical man-
ner, at three different depth levels collecting in total 10 ml of marrow. Furthermore, 
to compare the cellular differences between a BMC injectate and a BMA injectate 
(BMA-MC), we collected an additional 40 ml of BMA with the Aspire system, 
after the first 10 ml. This allowed for a total processing volume of 60 ml to produce 
BMC. Laboratory analysis resolved that both BMA devices were almost similar with 
regard to cell viability and numbers. Interestingly, with regard to CFU-Fs, the data 
are in accordance with Hernigou [40], and the first marrow aspiration provides 
the highest number of CFU-Fs. However, when comparing the BMA-MC cellular 
composition (a patient treatment specimen) with the BMC treatment specimen, 
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significant differences occur. Centrifugation foremost significantly increases cells 
who take part in regenerative processes when compared to the BMA-MC product. 
In contrast the non-regenerative RBCs and PFH concentrations are significantly 
reduced in the treatment vial, while maintaining a higher cell viability after cen-
trifugation. Our findings, with regard to cellular enrichments comparing a BMA 
with a BMC, are in agreement with others [41, 110], but not regarding RBC content 
and PFH. The cell concentrations are not only depending on the centrifugation 
protocols and the final BMC volume but are contingent of a meticulously executed 
BMA procedure, maintaining high cell viability, with minimal cell destruction.
6.3 Not every bone marrow concentrate is born equal
Currently, eight BMC harvesting devices are available on the market, produc-
ing different formulations of BMC and tissue viabilities and yielding different 
cellular concentration characteristics [111, 112]. As such, BMC preparations may 
vary widely regarding HSCs, MSCs, progenitors, platelet growth factors, and RBC 
content. Given this heterogeneity, the impact of BMC therapies on tissue regen-
eration may vary greatly. Explicitly, it is important to understand that the BMC 
Figure 12. 
Pathophysiological effects and reactions of RBCs in BMC vials. In absence of scavengers and compensatory 
mechanisms, PFH split products can lead to toxic consequences like inflammation and prooxidant 
effects, endothelial cell dysfunction, and vasoconstriction. Biological treatment specimen, containing high 
concentrations of RBCs, will lead to RBC cell membrane disruption (eryptosis,) releasing macrophage 
migration inhibitory factor (MIF) (courtesy of P. Everts and modified from Schaer et al. [109]).
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non-stem cell cellular components in the treatment vial might have significant 
roles regarding behavior and function of MSCs. Recently, the cellular variances 
were confirmed in a systematic review, evaluating BMC studies in musculoskeletal 
pathologies [53]. Presumably, as postulated by numerous authors, the variances in 
BMC cellular compositions have a significant effect on the biological activity and 
regenerative potency of the treatment specimen, and these inconsistencies impact 
clinical outcomes [111, 113]. Unfortunately, an exact understanding of the underly-
ing signaling relationships is not completely understood [114].
7. Bone marrow-derived mesenchymal cells in musculoskeletal disorders
The use of autologous BM-derived MSCs for the treatment of a variety of mus-
culoskeletal ailments is progressing significantly. Literature findings demonstrate 
positive outcomes after regenerative medicine MSC applications, in particular in 
joints, tendons, and bone, and hold great promise for future MSK-D applications, 
especially if more research and larger clinical trials are performed, focusing on cell 
validation processes and elucidating on potential dose responses.
7.1 Knee osteoarthritis
In this section we will present several clinical studies in which autologous, heter-
ogenous BMC was used as a regenerative biologic to treat a variety of musculoskel-
etal disorders [42, 115]. Studies reporting on similar pathologies using BM-derived/
cultured MSCs are not mentioned as it has been reported that these technologies 
have different biomedical properties and extraction methods [116] and potentially 
possess new challenges and indications, when compared to at POC prepared fresh 
autologous BMCs. In clinical settings, BMC has been exploited as an ortho-biologi-
cal treatment option for a range of indications, like symptomatic focal femoral head 
osteonecrosis, OA of the knee and hip, focal chondral defects, as well as another 
MSK-D. The rationale to use autologous BMC in osteoarthritic (OA) joints and other 
indications is its potential in facilitating anti-inflammatory and anabolic effects 
after injection. Moreover, the heterogenous BMC cellular assortment is known for 
its angiogenetic properties, therefore contributing to chondrocyte metabolism and 
inducing homing of (progenitor) stem cells to the treated areas [117]. Rodriguez-
Fotan and co-workers used a two-step BMC preparation protocol in patients 
with early onset of OA in the knee or hip (Kellgren-Lawrence grades I–II, Tönnis 
grades I–II, respectively), with BMA aspirated from the anterior iliac crest. After 
a single BMC injection, 63% of treated patients had improved clinical symptoms 
at 6-month postinjection. They concluded that the intra-articular BMC injections 
are safe procedures and no adverse events were reported [118]. In a prospective 
single-blind, placebo-controlled trial, 25 patients with bilateral knee OA and a 
median age of 60 years were randomized to receive BMC into one knee and saline 
placebo into the contralateral knee, thereby utilizing each patient as his/her own 
control. Safety data, effect of pain relief, knee function (Osteoarthritis Research 
Society International) measures, and the visual analog scale (VAS) for pain 
were observed until 6 months after the injections [119]. However, no differences 
between the two groups were observed. Of interest in this study was that the final 
injectate composition consisted of a mix of BMC and BMPF suspension. However, 
the eventual consequences of diluting BMC with BMPF on outcomes were not 
discussed. In another case series by Kim et al., a more invasive treatment approach 
was used. BMC was mixed with adipose tissue as a multi-tissue preparation for knee 
OA injections, in patients with a mean age of 60.7 years. At 9-month follow-up, 
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all patients showed clinical improvement, with satisfactory results in 70.7% of 
patients [120]. Remarkably, the authors found that patients with inferior treat-
ment results had a greater severity of OA prior treatment, as they were marked at 
Kellgren-Lawrence grade IV, suggesting that advanced OA may be more restrained 
to BMC therapy. The side effects encountered in this study, joint inflammation 
and pain, were in accordance with data from Rodriguez-Fotan [118]. Recently, a 
similar (retrospective) study was executed by Mautner and associates. Patients 
were prospectively treated either with bone marrow aspirate concentrate (BMAC) 
or micro-fragmented adipose tissue (MFAT) injections, for symptomatic knee OA 
[121]. The follow-up responses consisted of 76 patients (with 106 knees). The Knee 
Injury and Osteoarthritis Outcome Score (KOOS) questionnaire, Emory Quality of 
Life (EQOL) questionnaire, and VAS for pain were compared with baseline scores 
for all patients, and outcomes between BMAC and MFAT groups were evaluated. 
Data demonstrated a significant improvement in joint function and VAS pain scores 
after both MFAT and BMAC injections. No significant difference between the two 
autologous biological groups was demonstrating that BM- or adipose tissue-derived 
ortho-biological injections resulted in similar functional improvements.
7.2 Shoulder disorders
Lately, Darrow et al. reported on patients treated for shoulder osteoarthritis 
or rotator cuff tears (N = 50), with either BMC or BMA injections. Patients were 
grouped in receiving one or two injections [122]. Outcome reports included resting 
pain, active pain, upper extremity functionality scale, and overall improvement 
percentage. Data were compared to baseline and between the two groups. All 
patients had significant posttreatment improvements in resting pain, active pain, 
and functionality scores, when compared to baseline values. Patients receiving two 
treatments, average interval duration of 22 days, experienced statistically signifi-
cant more improvements in active pain than the patients receiving one injection. 
There were no significant outcome differences between patients with a rotator cuff 
tear or OA. Unfortunately, no information was provided on the BMA and BMC 
procedure, and no laboratory validation data were reported.
7.3 Osteonecrosis
Philippe Hernigou, world renowned for treating femoral head osteonecrosis, 
advocates the use of autologous BMC cell therapies [123]. He described a substantial 
repair and stabilization of necrotic femoral heads with percutaneous injection of 
autologous BMC, in combination with surgical core decompression. In a later paper, 
he reviews three decades of BMC therapies in hip osteonecrosis, emphasizing the 
quality of the BMC and cellular competence and addressing the effects of BM cell 
concentrates on the microenvironmental changes within osteonecrotic bone [124]. 
Other groups reported on prospective randomized clinical trials for femoral head 
osteonecrosis, comparing surgical decompression alone versus decompression 
augmented by autologous BMC preparations. The biologics were implanted during 
the surgical decompression procedure. In one study, patients were evaluated using 
the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index 
questionnaire, VAS pain index, and MRI. The mean WOMAC and VAS scores in all 
patients improved significantly (P < 0.001). Post-procedural MRIs showed a sig-
nificant (P = 0.046) improvement in patients in whom the surgical procedure was 
combined with BMC [125]. In a similar study, a significant decrease in pain associ-
ated with a functional benefit lasting the entire observation period was observed 
in the BMC-treated patients. However, no difference in clinical outcomes between 
27
The Rationale of Autologously Prepared Bone Marrow Aspirate Concentrate for use…
DOI: http://dx.doi.org/10.5772/intechopen.91310
the two study groups was seen during a 2-year follow-up period, with no significant 
difference between the femoral head survival rate [126]. Importantly, they analyzed 
the MSC and nuclear cell content of the BMC. There was a significant rise in nuclear 
cells and CFU-Fs (6.3-fold and 1.5-fold baseline values, respectively). Despite a 
significant rise in CFU-Fs in the BMC, the total deliverable MSC cell counts were 
relatively low. This might be related to the design features and specifications of the 
fully automated, sensor-controlled processing BMC device that was used with a 
single-step centrifugation protocol.
7.4 Cartilage repair
Awad and associates recently published a meta-analysis on knee cartilage repair 
[127]. They conducted a systematic review using the PRISMA guidelines and the 
Cochrane Handbook for Systematic Reviews of Interventions. A meta-analysis was 
conducted to estimate the effect size for function and pain in 724 patients, with a 
mean age of 44.2 years. In this review, both cultured BM-MSCs and autologous non-
cultured BMC were used. All autologous BMC treatment specimens were prepared 
following a two-step centrifugation method. Their most important meta-analytic 
finding was that the administration of non-cultured, fresh, BMC significantly 
reduced pain and improved knee function. This might be induced by the heteroge-
neous composition of the non-cultured BMC, as all constituents will synergistically 
foster cartilage regeneration and local pain management. Furthermore, BMC holds 
a certain volume of autologous plasma which can function as a cellular scaffold 
with the advantage of a more sustained release, compared to a pure cultured MSC 
product.
7.5 Tendinopathies
In a retrospective study, Stein et al. used BMC for primary Achilles tendon 
repairs, following traumatic injuries [128]. The BMC was adjunct to augment the 
surgical correction. Although the study lacked a control group, at a mean follow-
up of 30 months, there were no re-ruptures reported. In a small patient study, 
centrifuged BMC specimen were injected in patients, refractory to conservative 
therapies, with clinical and radiological evidence of chronic patellar tendinopathy. 
Long-term follow-up showed statistically significant improvement in the major-
ity of its reported scores [129]. A series of patients, diagnosed with clinical lateral 
epicondylitis, were treated with a single-spin BMC protocol. A significant improve-
ment was noted when pre-BMC scores were compared with postinjection scores, at 
12-weekpost-intervention. The authors suggested that BMC injections in patients 
who have failed non-operative treatment, before a surgical intervention, should 
be considered, and in their belief BMC injections can be developed as second-line 
conservative treatment in chronic tendinopathy, potentially reversing the degenera-
tive process [130].
8. Bone marrow concentrates in spinal disorders
Degenerative disk disease (DDD) affects the disks that separate the spine 
bones. Age-related changes can lead to arthritis, disk herniation, or spinal stenosis. 
Pressure on the spinal cord and nerves may cause pain. DDD is associated with 
significant morbidity. Conservative treatment options, physical therapy, self-care, 
medication, and spinal injections are used to manage the symptoms. However, these 
measures are often not significantly responsive. Surgery has been an option if the 
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pain is chronic. Nowadays, autologous regenerative applications have been made 
available to patients as an alternative treatment option.
8.1 Degenerative disk disease
Pettine et al. studied the use of intra-discal BMC injections in patients with 
DDD [131]. The authors injected 26 symptomatic patients for lumbar diskogenic 
back pain and disability and evaluated their postinjection outcomes using disability 
scores, pain scores, and MRIs. At 2-year follow-up, patients experienced significant 
improvements in disability and pain scores. This group was the first to report on 
MSC dose-dependent outcome responses. Patients receiving greater concentrations 
of autologous BM-MSC (expressed as CFU-Fs > 2000/ml) experienced a faster 
and greater reduction in pain scores. Later, these findings were strengthened with 
a follow-up study at 36 months, showing similar outcome results [43]. At 5-year 
follow-up, absolute and percentage reductions in pain and disability scores were 
sustained, with no adverse events reported through the 5-year follow-up period 
[132]. The American Society of Interventional Pain Physicians published recently 
guidelines addressing responsible and safe use of autologous biologics in the 
management of lower back pain [133]. Their extensive analysis revealed that there 
is level III evidence for the use of PRP and BM-MSCs. The guidelines also state that, 
following diagnostic evidence, regenerative therapies should be provided to patients 
as an independent therapy. If appropriate and indicated, regenerative therapies can 
be combined with conventional medicinal therapy or in conjunction with physical 
and behavioral therapy.
8.2 Spinal surgery
Hart et al. informed on a prospective, randomized, and blinded study in patients 
with lumbar disease the use of BMC mixed with allograft spongiosa chips during 
surgical posterolateral fusion (PLF) procedures. Patients underwent instrumented 
lumbar spine PLF procedures [134]. Fusion status and the degree of mineraliza-
tion were evaluated by two radiologists blinded to patient group affiliation. X-ray 
examination, in control patients at 12-month follow-up, showed that the bone graft 
mass fused in none of the cases and, at 24-months, in four cases (10%). In the BMC 
treatment group, 6 cases (15%) achieved fusion at 12 months and 14 cases (35%) at 
24 months. Computed tomography scans showed that 40% of control patients and 
80% of BMC-treated patients had evidence of at least a unilateral continuous bridg-
ing of the bones between neighboring vertebrae at 24 months, significantly favoring 
the mixture of spongiosa bone with autologous BMC (P < 0.05) as an efficient 
option to augment PLF healing.
9. Bone marrow concentrates in chronic wounds
Cell-based therapies are an attractive approach for the treatment of recalcitrant 
chronic wounds. BM-MSCs have been studied as a therapeutic strategy in chronic 
hard-to-heal wounds [135]. The orchestrated process of wound healing entails 
cellular and hormonal physiological processes in inflammation, proliferation, 
collagen matrix formation, and epithelialization which are regulated by various 
platelet-derived growth factors, such as TGF-b, VEGF, PDGF, granulocyte-
macrophage colony-stimulating factor, the interleukin family, EGF, FGF, and TNF-a 
[44, 105]. In chronic, poor-healing wounds, the activity and effectivity of growth 
factors and cytokines are often reduced due to a chronically inflamed wound. 
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Under these conditions the neo-angiogenetic wound healing potential is reduced, 
resulting in poor or no full wound epithelialization. The rationale for using BMC 
in these patients is the potential to modulate the immune response and secreting 
paracrine factors which promote (neo) angiogenesis, thereby providing biological 
ingredients for wound tissue repair that can jumpstart full wound closure [76, 136]. 
Optimal wound bed preparation is of the essence in wound healing strategies and 
encompasses tissue debridement with proper management of the bacterial load. 
Based on BM-MSC characteristics and their biological activity, MSCs are capable 
of interacting with resident wound cells to transform resident cells to functional 
matrix building cells, as described by Balaji et al. [137]. This finding might be of 
particular importance for dermal rebuilding processes, to stimulate (transplanted) 
keratinocyte-mediated wound epithelialization.
10. Bone marrow concentrates in critical limb ischemia
Patients with significant, below the knee, vascular diseases and who are, first 
of all, not eligible for revascularization surgery or endovascular treatments due 
to several comorbidities or have high operative risk and had multiple failures 
of revascularization or high rate of re-stenosis, might be suitable candidates for 
biological cell-based therapy with BM-MSCs. Patients diagnosed with critical 
limb ischemia (CLI) might also suffer from chronic non-healing wounds, and the 
estimated amputation and mortality rates are high [138]. The application of regen-
erative medicine therapies, in particular the use of BM-MSCs protocols, has merged 
as a treatment option in patients with CLI. In these patients, the justification to use 
BMC is to promote the regeneration of impaired endothelium and stimulate neo-
angiogenesis in ischemic areas [139]. Several varieties of BM-MSC therapies have 
been studied in CLI patients, ranging from BM-derived mononuclear cells, CD34+ 
BM cells, to mesenchymal stromal cells. The outcomes of cell-based trials have been 
encouraging and demonstrated a significant decrease in the rate of amputation 
[140]. It can be concluded that BM-MSC applications have the potential to modify 
the natural history of intractable CLI, while high-quality randomized trials are 
needed [45].
11. Conclusions
Regenerative medicine technologies offer solutions to a number of compel-
ling clinical problems that have not been able to adequately result in a solution 
through the use of drugs, surgery, or permanent replacement devices. Reviewing 
the last decades regarding autologous biological therapies, BM-MSCs have gained 
great interest. The purpose of this chapter was to review specific characteristics of 
bone marrow tissue and its cellular content, in particular the mesenchymal stem 
cells. Considerations when performing aspiration techniques and bone marrow 
concentrate preparations were presented, including explicit roles of hematopoietic 
and mesenchymal stem cells and other cytokines. Among autologous tissue-based 
cellular therapies, bone marrow mesenchymal cell therapies have been the most 
frequently employed and reported on, despite the fact that effects of coadjuvants, 
dosing, repetitive procedures, etc. are not yet established. Cultured MSC thera-
peutic interventions require strict procedures and biological license agreements, 
making them less attractive for same-day regenerative therapies. Using at POC 
BM-MSC concentrates overcomes these lengthy regulatory processes without the 
need for mandates. Clinical translation of BM-MSC-based therapies remains a work 
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in progress, as proper standardization has not yet been recognized [53]. However, in 
the clinical setting, effective and safe autologous BMA harvesting and preparation 
of BMC have been reported [42]. More, better, organized randomized clinical trials 
that are warranted with accurate follow-up data revealing the efficacy of BM-MSC 
therapy, including laboratory validation of the used products, should be a future 
goal. Furthermore, proper deliberations should manage the enormous variability 
aspects, like aspiration techniques, imaging options and procedures, BMC prepara-
tion protocols, effect of patient age, as well as tissue disease state. Therapy failures 
should also be highlighted in order to understand how they impact the therapy 
outcomes. Ultimately, the adoption of an accepted standard of overall regenerative 
biological preparations, including critical and ambivalent nuances, is crucial for 
future regenerative medicine practices.
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